Tony Hoos currently serves as the Chief of Medical for Amgen in Europe, which includes all therapeutic areas as well as all medical departments in Europe. Tony has been passionate about patient involvement in the development and life cycle of medicines for many years. He has worked extensively with stakeholders to involve patients in the benefit-risk assessment of medicines and he is one of the founders of ‘Patient Focused Medicines Development’ (PFMD), which is a multi-stakeholder initiative consisting of patient organizations and industry in the US and Europe.
Prior to Amgen, Tony was a Senior Vice President for GSK at the corporate headquarters in London; his responsibilities over time included European Medical Affairs, Head of the Rare Disease Business Unit and senior associate of the Chief Medical Officer. Prior to joining GSK, Tony was a member of the Executive Management Board of Merck Serono (Geneva, Switzerland); his area of responsibility was Global Drug Development, including Regulatory Affairs, Pharmacovigilance and Medical Affairs. Overall Tony has 25 years of experience in pharmaceutical industry in various global management and medicines development roles for companies in the United States and Europe, including a long career with Aventis and its predecessor companies. Dr. Hoos is a licensed physician; he studied and trained in Germany and the US. He also holds a Masters of Business Administration from the University of Toronto, Canada.
The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition, managed in collaboration with The Synergist. Its goal is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework. PFMD seeks to have a balanced representation of stakeholders to ensure transparency, inclusiveness, and credibility. Stakeholders include patients and patient organizations across diverse areas of health and industry. We also intend to invite regulators, payers and other professional organizations to the global group to ensure diversity of perspectives.
PFMD Board Meeting
Culture and Process Change as a Priority for Patient Engagement in Medicines Development - Article
12 Jan 2018
Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action - Article
12 Jan 2018
What do stakeholders expect from patient engagement: Are these expectations being met? - Report
03 Sep 2018